Clinical Trials

44 results for Bladder Cancer


Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy

  • Condition: Healthy Control, Localized Urothelial Carcinoma of the Renal Pelvis and Ureter, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bl
  • Intervention: Other: Cytology Specimen Collection Procedure, Other: Laboratory Biomarker Analysis
  • Study ID: NCT01050504
View Trial

Familial and Atypical Urothelial Cancer Registry

  • Condition: Urothelial Cancer, Renal Pelvis Cancer, Ureter Cancer, Bladder Cancer
  • Intervention: Other: saliva sample and questionaire, Other: saliva sample, questionaire
  • Study ID: NCT00902590
View Trial

A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer

  • Condition: Infiltrating Bladder Urothelial Carcinoma
  • Intervention: Other: Radiation + cisplatin, Other: Radiation + cisplatin + gemcitabine
  • Study ID: NCT01495676
View Trial

Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer

  • Condition: Bladder Cancer
  • Intervention: Drug: Pembrolizumab, Drug: Cisplatin, Radiation: Radiotherapy
  • Study ID: NCT02662062
View Trial

A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer

  • Condition: Urothelial Cancer
  • Intervention: Biological: nivolumab, Biological: ipilimumab, Drug: Gemcitabine, Drug: cisplatin, Drug: carboplatin
  • Study ID: NCT03036098
View Trial

Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging

  • Condition: Muscle-invasive Bladder Cancer
  • Intervention: Other: Whole-body FDG PET-CT
  • Study ID: NCT02462239
View Trial

Phase I Study of Hypofractionated Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) in the Treatment of Advanced Bladder Cancer

  • Condition: Invasive Bladder Cancer
  • Intervention: Drug: Pembrolizumab, Radiation: Radiotherapy
  • Study ID: NCT02560636
View Trial

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)

  • Condition: Cholangiocarcinoma, Gall Bladder Carcinoma
  • Intervention: Drug: Gemcitabine, Drug: Cisplatin, Other: Observation
  • Study ID: NCT02170090
View Trial

Prospective Randomized Trial of Adjuvant Radiotherapy Following Surgery and Chemotherapy in Muscle Invasive Transitional Cell Carcinoma of Urinary Bladder

  • Condition: Bladder Cancer, Urothelial Carcinoma Bladder
  • Intervention: Radiation: Adjuvant RT
  • Study ID: NCT02951325
View Trial

A Phase II Study of the Anti-PD-L1 Antibody MPDL3280A in Subjects With Non-metastatic Transitional Cell Carcinoma of the Bladder

  • Condition: Carcinoma, Transitional Cell
  • Intervention: Drug: MPDL3280A Dose Level 1, Drug: MPDL3280A Dose Level 2, Drug: MPDL3280A Dose Level 3
  • Study ID: NCT02451423
View Trial

Lymphadenectomy in Urothelial Carcinoma in the Renal Pelvis and Ureter

  • Condition: Ureteral Neoplasms [C12.758.820.875]
  • Intervention: Procedure: Lymphadenectomy in conjugation with nephroureterectomy, Procedure: Nephroureterectomy without lymphadenectomy
  • Study ID: NCT02607709
View Trial

A Phase II Open Label Single Arm Study of Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT)

  • Condition: Bladder Cancer
  • Intervention: Drug: Nivolumab
  • Study ID: NCT03171025
View Trial

A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With FGF

  • Condition: Urothelial Cancer
  • Intervention: Drug: JNJ-42756493
  • Study ID: NCT02365597
View Trial

A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-7435) for Metastatic Urothelial Cancer Refractory to Platinum

  • Condition: Stage IV Bladder Urothelial Carcinoma
  • Intervention: Procedure: Computed Tomography, Other: Laboratory Biomarker Analysis, Biological: Pembrolizumab, Procedure: Positron Emission Tomography, Biological: Recombinant EphB4-HSA Fusion Protein
  • Study ID: NCT02717156
View Trial

An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab (MK-3475) Before Cystectomy for Patients With Muscle-invasive Urothelial Bladder Cancer.

  • Condition: Urothelial Bladder Carcinoma
  • Intervention: Drug: Pembrolizumab (MK-3475)
  • Study ID: NCT02736266
View Trial

Randomized Phase II Study of Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder

  • Condition: Urothelial Carcinoma, Bladder Cancer
  • Intervention: Drug: Nivolumab in combination with Urelumab, Drug: Nivolumab monotherapy
  • Study ID: NCT02845323
View Trial

A Phase 1b Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Immune Checkpoint Inhibitor (CPI) Therapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer

  • Condition: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms
  • Intervention: Drug: enfortumab vedotin, Drug: pembrolizumab, Drug: atezolizumab
  • Study ID: NCT03288545
View Trial

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

  • Condition: Urothelial Carcinoma, Renal Cell Carcinoma
  • Intervention: Drug: cabozantinib, Drug: atezolizumab, Drug: cabozantinib
  • Study ID: NCT03170960
View Trial

A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicinium (Oportuzumab Monatox, VB4-845) in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With BCG

  • Condition: Urinary Bladder Neoplasms
  • Intervention: Drug: Durvalumab, Drug: Vicinium
  • Study ID: NCT03258593
View Trial

A Pilot Study to Evaluate the Safety of Neoadjuvant Nivolumab Alone or in Combination With Ipilimumab for Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (CA209-9DJ)

  • Condition: Bladder Cancer
  • Intervention: Drug: Nivolumab, Drug: Ipilimumab, Procedure: Radical cystectomy
  • Study ID: NCT03520491
View Trial

Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)

  • Condition: Metastatic Urothelial Carcinoma, Bladder Cancer
  • Intervention: Drug: Cabozantinib, Drug: Pembrolizumab
  • Study ID: NCT03534804
View Trial

Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma: A Feasibility Phase II Randomized Clinical Trial ("URANUS")"

  • Condition: Upper Tract Urothelial Carcinoma
  • Intervention: Procedure: RNU, Drug: Gemcitabine/Cisplatin, Drug: M-VAC Protocol
  • Study ID: NCT02969083
View Trial

Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy

  • Condition: Urothelial Carcinoma
  • Intervention: Drug: Sacituzumab govitecan
  • Study ID: NCT03547973
View Trial

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Car

  • Condition: Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
  • Intervention: Drug: Durvalumab, Drug: Tremelimumab, Drug: Cisplatin + Gemcitabine, Drug: Carboplatin + Gemcitabine
  • Study ID: NCT03682068
View Trial

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)

  • Condition: Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage III Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
  • Intervention: Drug: Atezolizumab, Drug: Cisplatin, Drug: Fluorouracil, Drug: Gemcitabine, Drug: Mitomycin, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Other: Survey Administration
  • Study ID: NCT03775265
View Trial

Pilot Study of Celecoxib Combined With Gemcitabine and Cisplatin for Neoadjuvant Treatment of Localized, Muscle-Invasive Bladder Cancer

  • Condition: Bladder Cancer
  • Intervention: Drug: Celecoxib, Drug: Gemcitabine, Drug: Cisplatin
  • Study ID: NCT02885974
View Trial

A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle-

  • Condition: Bladder Cancer, Muscle-Invasive Bladder Cancer, BMS-986205
  • Intervention: Biological: Nivolumab, Drug: BMS-986205, Drug: Gemcitabine, Drug: Cisplatin, Drug: BMS-986205 Placebo
  • Study ID: NCT03661320
View Trial

An International, Multicenter, Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab as First-line Treatment in Cisplatin-ineligible Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma

  • Condition: Urothelial Carcinoma
  • Intervention: Drug: Rogaratinib (BAY1163877), Drug: Atezolizumab, Drug: Placebo
  • Study ID: NCT03473756
View Trial

A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL-7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

  • Condition: Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurre
  • Intervention: Drug: Atezolizumab, Biological: Glycosylated Recombinant Human Interleukin-7, Other: Laboratory Biomarker Analysis
  • Study ID: NCT03513952
View Trial

A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors

  • Condition: HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer, HER2-positive Solid Tumor
  • Intervention: Drug: PRS-343
  • Study ID: NCT03330561
View Trial

Cabozantinib Plus Durvalumab in Patients With Advanced and Chemotherapy-treated Bladder Carcinoma, of Urothelial and Non-urothelial Histology: an Open-label, Single-centre, Phase 2, Single-arm Proof-of-concept Trial: ARCADIA Study

  • Condition: Bladder Carcinoma
  • Intervention: Drug: Cabozantinib, Drug: Durvalumab
  • Study ID: NCT03824691
View Trial

Efficacy and Safety of Neoadjuvant Chemotherapy With Dose Dense MVAC Followed by Radical Surgery in Patients With MIBC and Locally Advanced Urothelial Carcinoma of Bladder: Phase II, Single-arm Study

  • Condition: Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Neoadjuvant Chemotherapy
  • Intervention: Drug: dose dense MVAC with pegylated GCSF
  • Study ID: NCT04047693
View Trial

A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-

  • Condition: Urinary Bladder Cancer, Muscle-invasive
  • Intervention: Drug: Pembrolizumab, Drug: Gemcitabine, Drug: Cisplatin, Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Drug: Placebo
  • Study ID: NCT03924856
View Trial

A Phase 1b-2 Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study

  • Condition: Urinary Bladder Cancer, Invasive Bladder Cancer
  • Intervention: Combination Product: nivolumab 480mg, Combination Product: nivolumab 3mg/kg, ipilimumab 1mg/kg, Combination Product: nivolumab 1mg/kg, ipilimumab 3mg/kg
  • Study ID: NCT03844256
View Trial

A Pilot Study of 18Fluorine-Fluciclovine Positron Emission Tomography/Computed Tomography for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

  • Condition: Bladder Cancer, Urothelial Carcinoma
  • Intervention: Drug: 18F-fluciclovine, Device: PET/CT
  • Study ID: NCT04018053
View Trial

An Open-label, Dose-escalation, Bi-weekly Phase I+II Clinical Trial in Treating Patients With Locally Advanced and Metastatic Urothelial Carcinoma

  • Condition: Urothelial Carcinoma
  • Intervention: Drug: ZKAB001 5mg/kg, Drug: ZKAB001 10mg/kg, Drug: ZKAB001 15mg/kg
  • Study ID: NCT03676946
View Trial

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Co

  • Condition: Urothelial Carcinoma
  • Intervention: Drug: Atezolizumab, Drug: Enfortumab Vedotin, Drug: Niraparib, Drug: Hu5F9-G4, Drug: Isatuximab, Drug: Linagliptin, Drug: Tocilizumab
  • Study ID: NCT03869190
View Trial

A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

  • Condition: Bladder Cancer
  • Intervention: Drug: Durvalumab
  • Study ID: NCT03768570
View Trial

Phase II Study of Avelumab in Combination With AXL Inhibitor AVB-S6-500 in Patients With Advanced Urothelial Carcinoma

  • Condition: Urothelial Carcinoma
  • Intervention: Drug: Avelumab, Drug: AVB-S6-500
  • Study ID: NCT04004442
View Trial

A Phase II Study of Intermittent Checkpoint Inhibitor Therapy in Patients With Advanced Urothelial Carcinoma

  • Condition: Urothelial Carcinoma
  • Intervention: Drug: Pembrolizumab, Drug: Atezolizumab, Drug: Durvalumab, Drug: Nivolumab, Drug: Avelumab
  • Study ID: NCT04322643
View Trial

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEY

  • Condition: Urinary Bladder Neoplasms
  • Intervention: Drug: Pembrolizumab, Radiation: Conventional Radiotherapy (Bladder only), Radiation: Conventional Radiotherapy (Bladder and pelvic nodes), Radiation: Hypofractionated Radiotherapy (Bladder only), Drug: Cisplatin, Drug: Fluorouracil (5-FU), Drug: Mitomycin C (MMC), Drug: Gemcitabine, Drug: Placebo to Pembrolizumab
  • Study ID: NCT04241185
View Trial

Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)

  • Condition: Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer
  • Intervention: Drug: Infigratinib, Drug: Placebo
  • Study ID: NCT04197986
View Trial

Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy

  • Condition: Bladder Cancer, Bladder Cancer, Metastatic
  • Intervention: Drug: Atezolizumab
  • Study ID: NCT04138628
View Trial

A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)

  • Condition: Muscle Invasive Bladder Cancer
  • Study ID: NCT04700124
View Trial